Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.
We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color. By Jeremiah Johnson In February 2016, the CDC issued a new report with a…
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…
October 2016 Examples of media coverage: British scientists on brink of HIV cure (headline now corrected to “British scientists hopeful for HIV cure”) – The Sunday Times, October 2, 2016 (registration required) HIV cure close after disease ‘vanishes’ from blood of British man (now…
July 13, 2016 The consequences of stigma among people living with and vulnerable to HIV infection are significant and far-reaching. Stigma is frequently cited as a significant barrier to successful pre-exposure prophylaxis (PrEP) awareness, access and utilization. Despite having been…
A conference call meeting initiated by HIV community advocates was held with FDA members on June 10, 2016 to discuss ways to advance the evaluation and development of products (drugs or biologics) that demonstrate promise in improving health outcomes in HIV-positive patients with inadequate immune response after long term successful HIV treatment.
Dear Senator Sanders: We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS. Our group represents a larger coalition of over 70 organizations and advocates from across the country who hope to use this opportunity to push forward the national conversation, which is sorely missing, about HIV/AIDS. While we were optimistic following what we felt was a productive meeting, our optimism quickly turned to disappointment when your campaign issued a news release misrepresenting the meeting with HIV/AIDS leadership entitled “Sanders Backs California Ballot Initiative to Rein in Drug Prices at Meeting with HIV/AIDS Advocates.”
April 2016 The Daily Telegraph article and examples of the media coverage that followed it: Cure for HIV possible within three years as scientists snip virus from cells– The Daily Telegraph, April 1, 2016. Update April 6, 2016: After receiving complaints, The Daily…
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them By James Krellenstein and Jeremiah Johnson On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’…